GeneDx Holdings Corp. (WGS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneDx Holdings Corp. (WGS) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.77 Million) by net assets ($292.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GeneDx Holdings Corp. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how GeneDx Holdings Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GeneDx Holdings Corp. (WGS) financial obligations for a breakdown of total debt and financial obligations.
GeneDx Holdings Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneDx Holdings Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tabcorp Holdings Ltd
AU:TAH
|
0.075x |
|
Galapagos NV ADR
NASDAQ:GLPG
|
-0.013x |
|
Wuxi Paike New Materials Technology Co Ltd
SHG:605123
|
0.100x |
|
Bank of Zhengzhou Co Ltd Class A
SHE:002936
|
-0.076x |
|
Intapp Inc
NASDAQ:INTA
|
0.028x |
|
Autek China Inc
SHE:300595
|
0.054x |
|
Diamondrock Hospitality Company Common Stock
NYSE:DRH
|
0.047x |
|
TIANQI LITHIUM H YC 1
F:2220
|
N/A |
Annual Cash Flow Conversion Efficiency for GeneDx Holdings Corp. (2020–2024)
The table below shows the annual cash flow conversion efficiency of GeneDx Holdings Corp. from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see GeneDx Holdings Corp. (WGS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $245.25 Million | $-28.50 Million | -0.116x | +85.29% |
| 2023-12-31 | $228.02 Million | $-180.15 Million | -0.790x | +37.20% |
| 2022-12-31 | $253.71 Million | $-319.15 Million | -1.258x | -156.37% |
| 2021-12-31 | $388.10 Million | $-190.43 Million | -0.491x | +97.69% |
| 2020-12-31 | $4.39 Million | $-93.13 Million | -21.223x | -- |
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The compan… Read more